Anti-Fibrinolytic Drugs - Botswana

The Anti-Fibrinolytic Drugs market in Botswana is expected to reach a projected revenue of US$1.56m in 2024.
It is further anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 5.17%, leading to a market volume of US$2.01m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$9.86bn in 2024.
Despite being a developing country, Botswana has seen a significant increase in the demand for anti-fibrinolytic drugs due to its growing healthcare infrastructure and rising awareness about clotting disorders.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Botswana has been witnessing significant growth in recent years.

Customer preferences: The demand for Anti-Fibrinolytic Drugs in Botswana is primarily driven by the rising incidence of bleeding disorders. Patients suffering from hemophilia and other bleeding disorders require these drugs to prevent excessive bleeding and promote blood clotting. Additionally, the increasing awareness about the benefits of these drugs among healthcare professionals and patients is also contributing to the growth of the market.

Trends in the market: One of the key trends in the Anti-Fibrinolytic Drugs market in Botswana is the increasing adoption of generic drugs. Generic drugs are cost-effective and offer similar therapeutic benefits as branded drugs. This has led to a shift towards generic drugs, especially among low-income patients who cannot afford expensive branded drugs. Another trend is the rising use of combination therapy, where Anti-Fibrinolytic Drugs are used in combination with other drugs to enhance their therapeutic benefits.

Local special circumstances: Botswana has a high prevalence of HIV/AIDS, which has led to an increase in bleeding disorders such as hemophilia. According to the World Federation of Hemophilia, Botswana has one of the highest rates of hemophilia in Africa. This has led to a growing demand for Anti-Fibrinolytic Drugs in the country. Additionally, the government of Botswana has taken several initiatives to improve healthcare infrastructure and increase access to essential medicines, which has also contributed to the growth of the market.

Underlying macroeconomic factors: The Anti-Fibrinolytic Drugs market in Botswana is driven by several macroeconomic factors such as increasing healthcare expenditure, rising disposable income, and a growing geriatric population. The government of Botswana has been investing heavily in the healthcare sector to improve access to essential medicines and healthcare services. Additionally, the rising disposable income and growing geriatric population have led to an increase in demand for healthcare services, including Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.